Has Otis Brawley, MD received payments from drug or device companies?

Yes. Drug and device makers reported $88,813 in general payments to Otis Brawley, MD across 62 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Otis Brawley, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Otis Brawley, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Otis Brawley, MD

Hematology & Oncology · Atlanta, GANPI 1912915109

Payments from drug & device makers

$88,813in general payments, 2019–2025

Across 62 payments — averaging $1432.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Genentech, Inc.$58K
Astrazeneca UK Limited$21K
Genentech USA, Inc.$7K
Roche Diagnostics Corporation$3K
F. Hoffmann-la Roche AG$549

$7,065in research payments, 2019–2025

Across 2 payments — averaging $3532.34 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

F. Hoffmann-la Roche AG$7K

What the payments were for

Consulting fees$62,58370%
Speaking & faculty fees$2,6403%
Travel & lodging$21,19524%
Food & beverage$2,3953%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Genentech, Inc.	28	$58,204
Astrazeneca UK Limited	17	$20,640
Genentech USA, Inc.	8	$6,780
Roche Diagnostics Corporation	1	$2,640
F. Hoffmann-la Roche AG	8	$549

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

cobas Influenza A/B Nucleic acid test for use on the cobas Liat System$2,640

How this compares

$88,813 in reported general payments places this provider in the 75th percentile of 370 hematology & oncology providers in Georgia.

See all hematology & oncology providers in Georgia →

Medicare billing

Part B allowed, 2024

$40,119

Medicare patients

Services billed

2,155

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
XtandiEnzalutamide	15	$171,280
NubeqaDarolutamide	11	$148,640
Abiraterone Acetate	27	$82,810
Bicalutamide	11	$311

Paid to pharmacies, not to this prescriber.

Other hematology & oncology in Atlanta

Mehmet BilenAtlanta$21.7M
Ajay NookaAtlanta$19.3M
Olatunji AleseAtlanta$15.5M
Jonathon CohenAtlanta$8.7M
Ticiana LealAtlanta$6.1M
Conor SteuerAtlanta$4.4M
Anthony HunterAtlanta$4.3M
Robert BrownAtlanta$4.2M
Rodolfo BordoniAtlanta$4M
Kristie BlumAtlanta$3.7M

See the full list for Georgia →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →